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Case presentations
Patient 1. A 23-year-old, mentally retarded woman was admitted to
the hospital for evaluation of a pelvic mass. Noted to have ambiguous
genitalia at birth, the patient was raised as a boy until age 4. At that
time, she was hospitalized because of difficulty in urinating. The phallus
was intermediate in size; also present were a common urethral-vaginal
opening, nearly fused labioscrotal folds, and an inguinal hernia. Lapa-
rotomy disclosed a normal-appearing gonad on the left (thought to be an
ovary), no gonad on the right, and no uterus, but a white, string-like,
apparently solid structure that connected the broad ligaments and was
closely applied to a large, hypotonic bladder. The patient had a
clitorectomy and enlargement of the urethral orifice and was thereafter
raised as a girl. At age 12, she developed marked hirsutism and acne. At
age 20, chronic pyelonephritis was diagnosed, and an intravenous
pyelogram showed a double collecting system bilaterally, with left
hydronephrosis and hydroureters. At that time a firm, movable, midline
pelvic mass was noted during two physical examinations, but not on a
third, nor was the mass visible on the IVP.
The patient was a short, hirsute woman with low-set ears, a low
hairline, a broad chest with no breast development, and marked cubitus
valgus. Vital signs were normal. There were a male degree and
distribution of body hair, some temporal recession, and some mustache
hair. A complete blood count and other routine laboratory evaluations
were normal, including a serum creatinine level of 0.8 mg/dl and a
creatinine clearance of 130 liter/24 hr. Adrenal steroids were normal at
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baseline and after ACTH administration, and suppressed normally after
the patient was given dexamethasone. The plasma testosterone was 410
ng/dl and the response to human chorionic gonadotropin (HCG) was
that of a normal male.
Exploratory laparotomy showed a streak gonad on the right with
dysgenetic ovarian stroma, and a testis on the left with no germinal
epithelium but abundant Sertoli and Leydig cells. A thin-walled uterus
measuring 8 cm by 10 cm was present; it was distended with clear
yellow fluid. Biopsy revealed a thin squamous epithelium and well-
developed myometrium. Cytogenetic studies demonstrated 45.X/
45X(tY —* 13) mosaicism. Postoperatively, the plasma testosterone was
30 ng/dl; it did not increase after HCG administration.
Patient 2. A 72-year-old man was admitted to the hospital because of
urinary retention. For two years he had had difficulty in urinating; he
experienced urgency, frequency, intermittent abdominal pain, and
dribbling. One week prior to admission he was unable to void and went
to the hospital, where an IVP showed poor visualization. The serum
creatinine level was 10.4 mg/dl and the BUN was 120 mg/dl. A
retrograde pyelogram showed a patent left ureter and an obstructed
right ureter.
Physical examination revealed a blood pressure of 150/80 mm Hg;
basilar rales; and a 4+ enlarged, nontender prostate. The hematocrit
was 33%; white blood cell count, 11,000/mm3; BUN, 125 mg/dl; serum
creatinine, 7.8 mg/dl; arterial pH, 7.34; and pCO2, 36 mm Hg. A
transurethral prostatectomy was performed.
Patient 3. A 72-year-old-woman was evaluated for repeated urinary
tract infections. Her health had been good except for a cholecystectomy
at age 35 and a panhysterectomy at age 42. In the 5 years before
admission, she had had repeated episodes of urinary discomfort,
including burning and marked urgency with passage of small urine
volumes. No organism had been consistently isolated, but empiric use
of single-dose antibiotics apparently had been effective. In the past
several years she had noticed dyspareunia and occasional postcoital
staining.
Physical examination showed a slightly stooped, slender woman with
no abnormality save for a dry, shiny vaginal mucosa, with punctate
bleeding noted after the speculum was removed. The vaginal cytology
disclosed 100% parabasal cells, and the plasma level of follicle-stimulat-
ing hormone was over 100 lU/day.
Discussion
DR. DANIEL D. FEDERMAN (Dean for Students and Alumni,
and Professor of Medicine, Harvard Medical School, Boston,
Mass.): These patients illustrate the effects of sex hormones on
the lower urinary tract. In each case, the anatomy and clinical
picture are determined by an abnormality of gonadal steroid
production or effect. My discussion will deal with the underly-
ing anatomy and embryology, the normal endocrine physiology,
and the pathophysiologic disturbance that produces the clinical
picture. At the conclusion of my presentation, I shall comment
on the hormonal determinants of the behavioral aspects of these
disorders.
A chromosomal error leads to pyelonephritis
Let us discuss the first patient, who had ambiguous genitalia
at birth. Although reassigned at age 4 from a male to a female
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Fig. 1. Pelvic anatomy of Patient 1
gender role, at puberty she showed androgenic changes similar
to the masculinization that had occurred during embryologic
development. The evanescent abdominal mass is explained by
the drawing of her pelvic anatomy (Fig. I). Urine emerged from
the bladder, but voiding was restricted by an extremely small
urethral/vaginal orifice. The bladder emptied incompletely and
was thus palpable, and urine refluxed from the vestibule into
the uterus. Indeed, when the pathologist saw the removed
uterus at surgery, he said, 'My God, you've removed her
bladder!" In both shape and function the uterus had behaved
like a bladder, and it had developed a transitional epithelium.
To understand this patient's complex clinical picture, one
must understand the embryologic development of sexual identi-
ty [1]. Gonadal differentiation begins in a bipotential gonad
capable of forming either an ovary or a testis. In contrast, the
internal genital primordia are paired structures. All normal
embryos have both MUllerian and Wolifian ducts. In the normal
female, the Mullerian ducts give rise to the uterus, fallopian
tubes, and upper third of the vagina, and the Wolffian ducts
regress. In the male, the Woiffian ducts develop into the
epididymis, vas deferens, and seminal vesicle, and the Mullen-
an ducts regress. The external genitalia develop from midline
primordia which, with little change, yield a female appearance.
In the male, these structures fuse in the midline to produce the
penis and scrotum.
Gonadal and genital differentiation are controlled respective-
ly by chromosomal and hormonal influences. This concept
emerged from the study of three disorders of sex differentiation:
Turner's syndrome, testicular feminization, and steroid 5-al-
pha-reductase deficiency. In Turner's syndrome (gonadal dys-
genesis), the absence of definitive gonadal differentiation is
accompanied by female internal and external genitalia. The
characteristic cytogenetic abnormality is an absence of or
defect in the second sex chromosome. From this combination
of findings, we can infer that (1) the sex chromosomes deter-
mine gonadal differentiation, and (2) the indifferent genital state
of the human is female. In testicular feminization, resistance to
the action of testosterone is accompanied by complete Mullen-
an regression but absence of male internal or external genitalia.
Thus suppression of Müllerian differentiation is achieved by a
substance other than testosterone, the protein anti-Müllerian
hormone, but all male genital differentiation requires testoster-
one [21. In the syndrome of 5-alpha-reductase deficiency, in
which testosterone exists but dihydrotestosterone (DHT) does
not, the internal genitalia are male, but the external genitalia are
ambiguous or female. This observation confirms that DHT,
produced in the target tissues, and not testosterone, is responsi-
ble for external genital differentiation. In summary, normal
sexual differentiation requires chromosornally directed gonadal
induction, production of and response to two testicular hor-
mones, and end-organ metabolism of testosterone to DHT.
In the first patient under discussion, a chromosomal error
after fertilization resulted in sex chromosome mosaicism [3J.
Some cells had the 45,X karyotype characteristic of Turner's
syndrome, whereas others, although also having only 45 chro-
mosomes, bore a translocation of part of the Y chromosome to
chromosome 13. As a consequence, gonadal development was
asymmetric, and mixed gonadal dysgenesis resulted. The right
gonad was inactive, but the left secreted testosterone in
amounts sufficient to produce partial external virilization. The
abnormal urogenital differentiation led to urinary retention,
chronic pyelonephritis, and urinary incontinence, all despite
recruitment of the uterus as an accessory bladder. It is remark-
able that the endometrium served this function by developing
the transitional epithelium usually seen in the urinary tract
rather than maintaining the proliferative/secretory appearance
of an estrogen/progesterone target tissue.
Alteration in sex hormone metabolism produces prostatism
with obstruction
Now we will look at the second patient, an elderly male with
prostatism and renal failure. Approximately 80% of males in
western society ultimately manifest clinical effects of benign
prostatic hypertrophy (BPH). It seems likely that BPH is an
endocrine disorder of a special kind, so a review of the
development of the prostate and the related endocrine events
might be useful.
The prostate differentiates by a budding of ducts from the
urogenital epithelium. In elegant studies of this process, Cunha
and coworkers showed that control over prostate differentiation
is vested in the stroma and not in the epithelium [4]. Thus, if
prostate stroma is mixed with heterotopic epithelium, prostatic
glands differentiate in the epithelium; in contrast, if prostatic
epithelium is mixed with heterotopic stroma, prostatic glands
do not develop. Both the epithelium and the stroma require
exposure to androgen for full differentiation to occur.
The prostate weighs I g at birth, 4 g at puberty, and 20 g after
secondary sexual maturation. These milestones are reflected in
its histologic appearance. After initial embryonic differentia-
tion, the prostate appears inactive until puberty begins. At that
time a second phase of duct budding from the prostatic urethra
occurs. This process continues into early adult life and, in most
men, merges imperceptibly into a pathologic sequence that
eventuates in BPH [5]. The earliest evidence of the latter
process is recognized in the periurethral glands immediately
above the verumontanum, in the region of the urinary sphinc-
teric stroma.
Although BPH begins as a nodular hyperplasia of the peniur-
ethral glands, the stroma and myoepithelium are ultimately
included in the proliferation. In early life the outer portion of
the prostate is larger than the inner, but the proliferative
changes in the inner zone ultimately compress the outer zone
into a pseudocapsule. At this point encroachment on the
urethral lumen is common, but symptoms may be minimal.
labium minoris
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Eventually small infarcts, hemorrhages, and inflammation de-
velop, and these alterations can precipitate symptomatic uri-
nary retention. Intercurrent inflammation can regress, howev-
er, and for this reason, clinical prostatism is not always
relentlessly progressive but can be punctuated by symptomatic
improvement.
It had been known for many years that the prostate does not
develop in castrate or hypogonadal males; the newly defined
syndrome of 5-alpha-reductase deficiency, in which affected
individuals have testosterone but don't reduce it to DHT,
provides some insights into the process [6]. Although affected
individuals show dramatic virilization at puberty, the prostate
and the beard do not develop; thus DHT rather than testoster-
one is the principal androgen at those two sites. This observa-
tion in turn raised the possibility that BPH, like normal prostate
differentiation, might depend on DHT [7]. Further discussion of
the metabolism of testosterone can help us appreciate this
hypothesis.
Testosterone is produced by the Leydig cells of the testis in
response to luteinizing hormone from the anterior pituitary.
Plasma levels rise gradually during puberty and reach a plateau
of 300 to 1100 ng/dl, with some gradual diminution in later
years. Circulating testosterone is reversibly bound to a sex
steroid-binding globulin from which it dissociates and enters
target tissues by passive diffusion. In some but not all target
tissues, testosterone acts as a pre-hormone, being converted by
a cytosol 5-aipha-reductase into DHT. Both testosterone and
DHT bind to a cytosol androgen receptor and, after a change in
configuration, the hormone:receptor combination is translocat-
ed to the nucleus. Here it attaches to specific acceptor sites on
the nuclear chromatin and leads to selective DNA transcription,
mRNA production, the synthesis of specific proteins, and the
characteristic physiologic effect of the androgen.
A further step in the metabolism of DHT must be examined if
we are to understand the experimental evidence bearing on the
pathogenesis of BPH. Although the conversion of testosterone
to DHT is irreversible, DHT is reversibly metabolized to 5a-
androstanediol. These reactions are as follows:
Testosterone — dihydrotestosterone 5a-androstanediol
Thus the stage is set for accumulation of DHT in the prostate,
not through overproduction of testosterone but through either
increased conversion of testosterone to DHT or diminished
metabolism of DHT to 5a-androstanediol. Indeed, the following
evidence supports the hypothesis that BPH is due to an
abnormal accumulation of DHT. The dog is cited because it is
the only animal besides man in which a form of BPH occurs:
(1) the castrate dog and human do not develop BPH;
rather, the prostate atrophies;
(2) administration of DHT or 5a-androstanediol (back-
converted to DHT) induces BPH in the dog;
(3) pharmacologic inhibition of DHT generation pre-
vents or reverses BPH in the dog;
(4) the hypertrophic human prostate contains in-
creased amounts of DHT, and early in the course of
the disease, this increase is largely limited to the
periurethral tissue where BPH begins [81.
(5) the production of DHT from testosterone in the
prostate is minimally elevated, but there is a
marked reduction in the metabolism of DHT to 5-
androstanediol and an enhanced back-production
of DHT. Thus, a combination of changes in the
prostate leads to an accumulation of DHT that
gradually increases with age [9, 10].
The endocrine status of the older human male therefore can
be summarized as follows. Beginning at approximately age 60,
but proceeding variably in different individuals, plasma testos-
terone gradually decreases, plasma estradiol increases, and the
level of plasma DHT remains stable or increases. In the
prostate, testosterone entry is unimpaired, the conversion of
testosterone to DHT is slightly increased, and the net metabo-
lism of DHT to 5a-androstanediol is diminished. These changes
cause a gradual increase in prostatic mass, and a periurethral
nodular hyperplasia that ultimately compromises the urinary
stream and induces renal insufficiency. This concept of the
pathogenesis of BPH is now stimulating new approaches to
therapy, which I will return to later.
Hormonal deficiency can produce the "urethral syndrome"
The final patient is a 72-year-old woman thought to have had
recurrent urinary tract infections. Careful review of her medical
history disclosed that the evidence for urinary infection was
unimpressive, and that her symptoms were more those of the
"urethral syndrome." This formulation was supported by the
development of vaginal symptoms suggesting estrogen deficien-
cy and by the finding of a severely atrophic vaginal cytology.
Postmenopausal estrogen deficiency is first experienced by
most women as hot flushes. Although the flushes tend to
disappear within 3 to 5 years of the menopause, vaginal
discomfort is a consequence of estrogen deficiency that often
appears 10 to 20 years later. This manifestation is the result of
withdrawal of estrogen stimulation from the vaginal mucosa,
with consequent dryness and atrophy [11]. Evidence suggests
that regular sexual intercourse retards vaginal atrophy, and it is
thus particularly the woman who resumes coitus after a several-
year lapse who notices dyspareunia and occasional slight bleed-
ing from the irritated vaginal mucosa.
In a small number of patients, estrogen deficiency produces
the "urethral syndrome." These patients' symptoms, namely
urinary frequency, burning, and dysuria, simulate urinary tract
infection, but neither the history nor repeated urine cultures
disclose evidence of urinary tract infection [12]. The embryolo-
gy of the female urethra lays the groundwork for understanding
the pathogenesis of this syndrome. The distal portion of the
urethra, formed from the urogenital sinus, is an estrogen-
responsive tissue similar to the uterus and vagina. Estrogen
deficiency can produce atrophy of the mucosal barrier, allowing
an acid urine to inflame the urethra. This inflammation some-
times extends to the trigone and stimulates detrusor contrac-
tion. Atrophy can also increase the urethral diameter and
decrease a-adrenergic-stimulated urethral constriction. The
consequence can be urinary incontinence and its many damag-
ing physical and psychic sequelae. Thus, as estrogen levels fall,
genitourinary mucosal atrophy may show up as the "urethral
syndrome," incontinence, and annoying local symptoms.
Some uniflying principles
Several features of genital differentiation predispose to the
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pathologic syndromes that we have been discussing. First,
there is an overlap in embryologic origins between urinary and
genital structures. Second, these structures undergo initial
Jifferentiation during fetal life but have a second developmental
phase after puberty. In the male, both phases are mediated by
androgen; in the female, postpubertal development and mainte-
nance of the urogenital derivatives are estrogen dependent.
Finally, gonadal function varies with age. During the period of
sex differentiation, the fetal testis produces androgen, either
spontaneously or under the direction of chorionic gonadotropin
[131. In addition, neonates experience a transient phase of
pituitary-gonadal activity shortly after birth. Although more
striking in the male, this phase also occurs in the female [14].
During the rest of infancy and childhood, gonadal function is
quiescent. At puberty sex steroid production increases in
response to hypothalamic-pituitary activation. Finally, testos-
terone production in the male declines gradually but incom-
pletely after age 60, but estrogen production drops dramatically
in the female at menopause.
Understanding the pathogenesis of the disorders we have
looked at leads to rational and effective treatment. Newborns
with ambiguous genitalia can now be correctly diagnosed within
a few days of birth; corrective surgery and hormonal therapy
can restore these individuals to an almost wholly satisfactory
life. Similarly, estrogen substitution can correct the deficiency
symptoms of the menopause. But is there a prospect that
endocrine therapy can be developed to treat benign prostatic
hypertrophy? To understand the implications of this question, it
is necessary that we review the influence of sex steroids on
another of their target tissues—the nervous system.
Although relatively little is definitely known about the hor-
monal control of human sexuality, comparative studies have
demonstrated the anatomic basis for certain types of sexual
behavior. Nottebohm has shown in the finch that singing, an
exclusively male function, depends on three nuclei in the
central nervous system, the initial and annual development of
which are testosterone dependent [15]. These three nuclei are
larger in the normal male than are those in the female. Castrate
male finches do not sing, and their nuclei are the same size as
those in the female. When the castrate male is treated with
testosterone, the anatomic dimorphism and singing are both
restored. That is, a specific cytoarchitectonic change is accom-
panied by the restoration of a specific (sexual) behavior.
These observations in the finch have instructive resonances
in other species. Perinatal exposure of rodents to gonadal
steroids can permanently alter reproductive endocrine function
and related sexual behavior: thus female rodents exposed to
testosterone immediately after birth never develop estrus cy-
cles and display male copulatory behavior. Jacobson and
Gorski have described a sexually dimorphic nucleus in the rat
that is, as in the finch, androgen dependent [161. Sex hormones
can influence both dendritic arborization of neurons cultured in
vitro and the synthesis of neurotransmitters. Finally, certain
cells in the brain have steroid hormone receptors and the
enzymes to convert testosterone to DHT or to estradiol. Thus,
strong comparative evidence indicates an influence of gonadal
steroids on early differentiation and subsequent activation of
neural tissue.
Does anything similar happen in the human and, if so, when?
It is here that the temporal development of pituitary and
testicular activity is pertinent. Testosterone production is ac-
tive in mid-gestation, shortly after birth, and again at puberty.
Thus early surges of testosterone might be influential not only
on the reproductive anatomy but also on the brain. Subsequent
androgen production at puberty influences full sexual expres-
sion, including libido, potency, and ejaculation. None of these
develop or endure normally without testosterone.
One can now appreciate the new approaches to the preven-
lion and therapy of BPH. Previous efforts at controlling this
disease included inhibition of androgen production by estrogen
administration, and opposition to androgen action by drugs
such as cyproterone acetate. But these approaches are clinical-
ly unacceptable because they render the patient impotent. It is
in this connection that Sct-reductase deficiency becomes perti-
nent. Patients with this syndrome have ample testosterone but
diminished DHT, and yet they are sexually potent and have
normal libido. These findings suggest that a drug that competi-
tively antagonized the production of DHT from testosterone
would remove the hormonal stimulus to BPH but leave intact
the hormonal substrate of libido and potency.
Conclusion
In this Forum I have tried to account for several clinical
disorders affecting the lower urinary tract by reviewing the
embryologic mise en scene and the subsequent role of normal
and pathologic hormone states. It is conceivable that certain
renal diseases, particularly those with a sexually differentiated
incidence, may also be shown to depend at least in part on
endocrine mechanisms.
Questions and answers
DR. JORDAN COHEN: At what stage in embryonic develop-
ment is gender differentiation committed beyond retrieval? I
ask this question in the hope that emerging techniques for in-
utero diagnostic testing might someday be able to identify some
of these abnormalities in time to correct them.
DR. FEDERMAN: The testes differentiate at about 4 weeks, the
ovary at about 11 weeks. In the presence of testes, the Wolifian
ducts evolve into the vas and seminal vesicle by about 7 to 10
weeks, and the external genitalia are complete by 16 weeks. It
would be hard to imagine a diagnosis leading to an intrauterine
intervention because the events are at such a time that I think
the fetus would be inaccessible to surgery. After the 16th week,
all the genital tissues except the penis or clitoris lose their
sensitivity to androgen. The clitoris will still grow after that
time but the internal and external genitalia do not change after
about the 16th week.
DR. ARNON DREYFUSS (Medical Resident, NEMC): I under-
stand that the gene for the testosterone receptor is located on
the X chromosome. Do patients with several X chromosomes
have an increased number of testosterone receptors?
DR. FEDERMAN: No, consistent with the inactivation of all
but one X chromosome, the number of testosterone receptors is
independent of the total number of Xs beyond the first X.
DR. DREYFUSS: What are the other products of the Y
chromosome?
DR. FEDERMAN: No other discrete gene product of the Y
chromosome is known. There must, however, be some genetic
control of linear growth on the Y chromosome because, com-
pared to the 45,X Turner's patient who is short, the 46,XY male
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has normal growth. There is also a weak histocompatibility
antigen, called the HY antigen, which is determined by the Y
chromosome.
DR. JERRY MCCAULEY (Division of Nephrology, NEMC):
You cited evidence suggesting that BPH is associated with an
increase in DHT. Your discussion suggests a trophic function of
the hormone leading to an enlarged prostate. Another possible
explanation for these findings is that there is end-organ insensi-
tivity leading to elevated DHT levels. Is there evidence that
addresses this question? In addition, does the level of DHT
affect up- and down-regulation of receptors?
DR. FEDERMAN: Administration of DHT—or of smaller
amounts of 5s-androstanediol—leads to BPH in the dog. This
suggests that it is the presence of the increased amount of
hormone rather than a change in receptor affinity or number
that matters.
DR. COHEN: Is there any evidence that hypertrophy of the
prostate can regress if the gland comes out from under the
influence of DHT?
DR. FEDERMAN: There is some evidence for such regression,
but by the time the prostate is truly large, epithelial and stromal
growth often are accompanied by infarction, hemorrhage, and
inflammation. These secondary pathologic changes are not very
responsive to reducing the levels of DHT. So far the evidence
indicates that one can prevent enlargement more easily than
one can reverse it.
DR. JOHN T. HARRINOTON: You stated that DHT is active in
the central nervous system and in the prostate. Is it active
anywhere else in the body? What would happen if you could
inhibit DHT's action pharmacologically?
DR. FEDERMAN: That is precisely why the clinical syndrome
of steroid 5a-reductase deficiency is so important. Despite their
incomplete external differentiation, affected individuals have an
almost normal male puberty. They have a growth spurt, male
muscularity, a deep voice, and good penile and scrotal develop-
ment. In addition, they have male libido, a heterosexual object
choice, and satisfactory erectile function. The last is especially
important if one imagines treating BPH by inhibiting the 5a-
reductase. Estrogen would control BPH reasonably well but is
clinically unacceptable because it induces impotence. In con-
trast, testosterone without DHT is apparently adequate for
male sexuality.
DR. HARRINGTON: What, if anything, is known about vascu-
lar disease in patients with 5a-reductase deficiency?
DR. FEDERMAN: There aren't enough cases for us to answer
that question.
DR. RONALD PERRONE (Division of Nephrology, NEMC): In
the third case, you described an estrogen deficiency syndrome
that resulted in urethritis. Are there cytologic changes of the
anterior urethra that might be useful to us in making this
diagnosis? Is this syndrome treated with local or with systemic
estrogens?
DR. FEDERMAN: Yes, an experienced cytologist can recog-
nize estrogen deficiency in the epithelial cells of the urinary
sediment. In addition, physical examination reveals the inucosa
to be shiny, atrophic, and easily traumatized. The Papanicolaou
test of vaginal cytology also can be read for estrogen effect.
Severe estrogen deficiency results in 100% parabasal cells.
Treatment can be systemic or local. A diethylstilbestrol or
Premarin cream can be rubbed into the vagina—rather lightly
the first few times because the vagina is easily irritated.
Systemic estrogen also is highly effective. Indeed, most people
believe that locally applied estrogen has its effect largely
through being absorbed into the circulation. But one can use
estrogen either way, and, especially with women who are
reluctant to take medication, local treatment is quite
satisfactory.
DR. ANDREW LEVEY (Division of Nephrology, NEMC): Are
there cytologic changes in other parts of the urinary tract during
the menstrual cycle?
DR. FEDERMAN: Yes, the epithelial cells shed from the lower
urinary tract reflect the hormonal changes of the menstrual
cycle. That is not so of the upper urinary tract, which is not of
Müllerian origin.
DR. LEVEY: Does any other part of the urinary tract exhibit a
maleness or femaleness?
DR. FEDERMAN: In the rodent there are several renal en-
zymes, including alcohol dehydrogenase, that are testosterone
inducible. The liver is strikingly sexualized in both the mouse
and the rat, with a striking difference in the biochemistry of the
liver between the male and the female. Almost nothing is known
about that in humans, so I don't know of a sex dimorphism in
the liver of the human.
DR. LEVEY: What is your interpretation of the fact that few
renal cell carcinomas improve with sex-steroid hormonal
therapy?
DR. FEDERMAN: I don't know. One possibility would be that
there are receptors in the cancer tissue which, when exposed to
a large excess of hormone, pick up a small amount and respond
to it. The same receptors exposed to ordinary physiologic levels
of the hormone wouldn't show any effect. But that is purely
speculative.
DR. NJCOLAOS E. MADIAs: Has DHT been measured in
patients with prostatic cancer?
DR. FEDERMAN: Yes, and the levels are not abnormal. But
the anatomy of the two pathologic processes is different. Benign
prostatic hypertrophy begins in the pen-urethral zone of the
prostate; cancer generally originates in the outer zone. The
increase of DTH has only been found in the pen-urethral area.
DR. COHEN: You indicated that DHT levels are a function of
age whether or not prostatic hypertrophy is present. Yet almost
all the patients who had high DHT levels were elderly, and
almost all of these had BPH. Are there data from a sufficient
number of elderly men without BPH to verify that a high DHT
level rather than age itself is the critical variable?
DR. FEDERMAN: Although it is generally true that DHT levels
increase in older males, within a given age group there is a
broad range of DHT levels, and prostatic hypertrophy seems to
correlate with the higher levels of DHT. Several series support
that finding, but others do not.
DR. HARRINGTON: Is DHT involved in the inhibition of
Müllerian duct development in utero in females?
DR. FEDERMAN: No, MUllerian regression is promoted by
another compound called antimUllerian hormone or Mullenian-
regression factor. This is a protein hormone, not a steroid. It
acts locally and doesn't require either testosterone or DHT for
its action. So that seems to be a separate story.
Addendum
One day after this Forum was presented, a report appeared
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that contradicted the prior evidence that DHT levels are
increased in BPH. Using fresh surgical specimens and new
techniques, Walsh et al found no difference in DHT concentra-
tions in hyperplastic versus normal prostate [17].
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